查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細胞治療和基因治療供應鏈軟體市場 - 按流程組件、軟體類型、部署模式、業務規模、最終用戶類型、關鍵區域:行業趨勢和全球預測
市場調查報告書
商品編碼
1471914

細胞治療和基因治療供應鏈軟體市場 - 按流程組件、軟體類型、部署模式、業務規模、最終用戶類型、關鍵區域:行業趨勢和全球預測

Cell and Gene Therapy Supply Chain Software Market - Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-User and Key Geographical Regions : Industry Trends and Global Forecasts
出版日期: | 出版商: Roots Analysis | 英文 378 Pages | 商品交期: 最快1-2個工作天內

價格

到 2024 年，細胞和基因治療供應鏈軟體市場規模預計將達到 2,740 億美元，2024-2035 年預測期間複合年增長率為 15.2%。

開創性的細胞和基因療法引起了醫療保健領域的範式轉變，徹底改變了尖端醫療療法的開發、生產和消費。 這些突破性的治療方法使醫療保健專業人員能夠對抗曾經看似無法克服的罕見臨床疾病。 在過去的幾十年裡，此類變革性治療已獲得30 多個監管部門的批准，最近的成功案例包括ELEVIDYS(R) (2023) 和Adstiladrin(R) (2022)、Breyanzi (R) (2022)、CARVYKTI ( R) (2022)。 值得注意的是，自 2018 年以來，超過 40% 的罕見疾病臨床試驗涉及創新細胞和基因療法產品的評估。 根據目前研發管線和歷史臨床成功率的預測表明，到 2025 年，美國食品和藥物管理局每年可能會批准 10 至 20 種先進療法。 因此，對簡化供應鏈管理的創新軟體解決方案的需求將猛增，為細胞和基因治療軟體提供者創造成長機會。

重要的是，細胞和基因療法產品的商業成功不僅取決於其治療功效，還取決於開發人員無縫應對複雜供應鏈的能力。 由於其溫度敏感性和獨特性，細胞和基因治療產品的供應鏈本質上比傳統藥品供應鏈更複雜。 因此，療法開發人員必須應對各種風險，包括營運效率低下、產能調度挑戰、導致資本損失的流程延遲以及與運輸和追蹤相關的問題。 市場上正在見證旨在開發這些軟體解決方案的合作夥伴關係的激增。 此外，由於對具有成本效益的個人化藥物的需求不斷增加，以及透過實施此類軟體解決方案降低成本的潛力，細胞治療和基因治療供應鏈軟體市場預計將出現顯著增長。

本報告研究了全球細胞治療和基因治療供應鏈軟體市場，按流程組件、軟體類型、部署模式、業務規模、最終用戶類型和地區提供了市場概述及公司概況等。

目錄

第1章前言

第2章研究方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

  • 章節概述
  • 細胞療法概述
  • 先進治療藥物 (ATMP)
  • 細胞治療與基因治療供應鏈概述
  • 近期趨勢與未來展望

第6章市場狀況

第7章企業競爭分析

  • 章節概述
  • 假設和主要參數
  • 調查方法
  • 公司競爭分析：細胞與基因治療供應鏈軟體供應商

第8章公司簡介

第9章融資與投資分析

  • 章節概述
  • 融資模式
  • 細胞和基因治療供應鏈軟體：融資和投資分析
  • 結論

第 10 章夥伴關係與協作

第11章供應鏈軟體解決方案市場平台使用協定

第12章利害關係人需求分析

第 13 章市場影響分析：驅動因素、限制因素、機會、挑戰

  • 章節概述
  • 市場驅動因素
  • 市場限制
  • 市場機會
  • 市場挑戰
  • 結論

第 14 章全球細胞治療與基因治療供應鏈軟體市場

第 15 章細胞治療與基因治療供應鏈軟體市場：依流程組件劃分

第 16 章細胞治療與基因治療供應鏈軟體市場：依軟體類型

第 17 章細胞治療與基因治療供應鏈軟體市場：依部署模式

第 18 章細胞治療與基因治療供應鏈軟體市場：依業務規模劃分

第 19 章按最終使用者類型劃分的細胞治療和基因治療供應鏈軟體市場

第 20 章細胞治療與基因治療供應鏈軟體市場：按主要地區劃分

第21章結論

第 22 章高階主管洞察力

第 23 章附錄 1：表格資料

第 24 章附錄 2：公司與組織名單

Product Code: RA100140

The cell and gene therapy supply chain software market is valued at USD 274 billion in 2024 growing at a CAGR of 15.2% during the forecast period 2024-2035.

Pioneering cell and gene therapies have catalyzed a paradigm shift in healthcare delivery, revolutionizing the development, production, and consumption of cutting-edge medicine. These groundbreaking therapeutics have empowered healthcare professionals to combat rare clinical conditions that once seemed insurmountable. Over the past few decades, more than 30 such transformative modalities have garnered regulatory approval, with recent triumphs including ELEVIDYS(R) (2023), Adstiladrin(R) (2022), Breyanzi(R) (2022), CARVYKTI(R) (2022), Abecma(R) (2021), Allocord(TM) (2019), LUXTURNA(TM) (2017), and Yescarta(R) (2017). Moreover, a report by Novotech heralded the anticipated approval of more than 12 novel cell and gene therapies by the end of 2023, underscoring lucrative prospects for stakeholders in this burgeoning domain. Notably, post-2018, over 40% of clinical trials addressing rare diseases involved the evaluation of innovative cell and gene therapy products. Based on the current pipeline and historical clinical success rates, projections indicate that the United States Food and Drug Administration could approve 10-20 advanced therapies annually until 2025. Consequently, the demand for innovative software solutions to streamline supply chain management is poised to surge, presenting growth opportunities for cell and gene therapy software providers.

Importantly, the commercial triumph of cell and gene therapy products hinges not only on their therapeutic efficacy but also on developers' ability to seamlessly navigate complex supply chain intricacies. The cell and gene therapy supply chain is inherently more intricate than conventional pharmaceutical supply chains due to the temperature sensitivity and uniqueness of these products. Consequently, therapy developers must grapple with an array of risks, including operational inefficiencies, capacity scheduling challenges, process delays leading to capital losses, and delivery/tracking-related issues. This intricate landscape has fueled the need for tailored software solutions that can seamlessly integrate with existing processes, empowering drug developers to oversee and manage every aspect of the cell and gene therapy supply chain at each juncture. Over time, numerous innovative software solutions have emerged, offering supply chain orchestration and needle-to-needle traceability capabilities. The market has witnessed a surge in partnerships aimed at advancing these software solutions. Furthermore, driven by the growing demand for cost-effective personalized medicinal products and the cost-saving potential of implementing such software solutions, the cell and gene therapy supply chain software market is poised for substantial growth.

Key Market Segments

Process Component

  • Sample Collection and Processing Component
  • Manufacturing Component
  • Logistics Component
  • Patient Identification and Treatment Follow-up Component

Type of Software

  • Enterprise Manufacturing System (EMS)
  • Laboratory Information Management System (LIMS)
  • Inventory Management System (IMS)
  • Cell Orchestration Platform (COP)
  • Quality Management System (QMS)
  • Logistics Management System (LMS)
  • Patient Management System (PMS)

Mode of Deployment

  • On-premises Deployment
  • Cloud-based Deployment

Type of End-User

  • Pharmaceutical Companies
  • Cell Therapy Labs
  • Hospitals / Medical Centers
  • Research Institutes / Biobanks

Type of End-User

  • Clinical Scale
  • Commercial Scale

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the cell and gene therapy supply chain software market based on process component, type of software, mode of deployment, type of end-user, scale of operation and key geographical regions.
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • The report begins with a general overview of the cell and gene therapy supply chain, highlighting different types of software solutions, their key features, and applications. It also covers the advantages of supply chain software in this industry, challenges with conventional supply chains, and opportunities and future perspectives associated with supply chain management software.
  • It provides a detailed overview of the current market landscape for cell and gene therapy supply chain software solutions, based on parameters such as software type (cell orchestration platform, enterprise manufacturing system, inventory management system, laboratory information management system, logistics management system, patient management system, quality management system, and tracking and tracing system), key features (compatibility/integration, traceability, data analytics/visualization, scalability, user-friendliness, chain of identity/custody), application area, mode of deployment, scale of operation, regulatory guidelines followed, and end-user type. Additionally, it lists developers offering these solutions, analyzing them based on establishment year, company size, headquarters location, and active players.
  • The report offers an insightful competitiveness analysis of companies in this market, based on developer strength (experience, company size) and product portfolio strength (partnerships, application areas, features, end-users, deployment mode, operation scale, regulatory guidelines).
  • It includes elaborate profiles of key software providers, featuring company overviews, software portfolios, financial information, recent developments, and future outlooks.
  • The report provides an in-depth analysis of funding and investments in this domain since 2014, including seed funding, venture capital, debt financing, grants/awards, IPO proceeds, and subsequent offerings received by companies operating in this market.
  • It presents a detailed analysis of partnerships, including acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements, and others, inked between companies in this market since 2019.
  • The report offers an in-depth analysis of platform utilization agreements signed since 2019, providing information on different software types utilized by end-users in the cell and gene therapy supply chain.
  • It includes a qualitative assessment of current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers, regulators/payers) involved in the cell and gene therapy supply chain, highlighting the diverse needs and their impact on the supply chain and industry preparedness.
  • The report provides an in-depth analysis of factors impacting the growth of this market, including key drivers, potential restraints, emerging opportunities, and existing challenges.
  • It offers a detailed estimate of the current market size and future growth potential of the cell and gene therapy supply chain software market until 2035, based on likely adoption trends and reliable secondary and primary validations. The report features three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.
  • The report includes detailed projections of the current and future market opportunity across various process components (sample collection/processing, manufacturing, logistics, patient identification/treatment follow-up), software types, deployment modes, operation scales, end-user types, and key geographical regions.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the cell and gene therapy supply chain software market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Azenta Life Sciences
  • Biocair
  • BioLife Solutions
  • CareDx
  • Cryoport
  • Lonza
  • NMDP BioTherapies
  • TraceLink
  • TrakCel
  • Veeva Systems
  • Emerson
  • LabVantage Solutions
  • Marken
  • MasterControl
  • QuickSTAT
  • Siemens
  • Stafa Cellular Therapy
  • Steiner
  • STEMSOFT Software

TECHNIDATA

  • Thermo Fisher Scientific

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Cell Therapies
  • 5.3. Advanced Therapy Medicinal Products (ATMPs)
    • 5.3.1. Difference between Cell / Advanced Therapies and Other Biotechnology Products
  • 5.4. Overview of Cell and Gene Therapy Supply Chain
    • 5.4.1. Software Solutions for Cell and Gene Therapy Supply Chain
      • 5.4.1.1. Enterprise Manufacturing System (EMS)
      • 5.4.1.2. Laboratory Information Management System (LIMS)
      • 5.4.1.3. Inventory Management System (IMS)
      • 5.4.1.4. Quality Management System (QMS)
      • 5.4.1.5. Logistics Management System (LMS)
      • 5.4.1.6. Patient Management System (PMS)
      • 5.4.1.7. Cell Orchestration Platform (COP)
    • 5.4.2. Challenges in Cell and Advanced Therapy Supply Chain
  • 5.5. Recent Developments and Future Outlook

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Cell and Gene Therapy Supply Chain Software: Overall Market Landscape
    • 6.2.1. Analysis by Type of Software
    • 6.2.2. Analysis by Key Features
    • 6.2.3. Analysis by Application Area
    • 6.2.4. Analysis by Mode of Deployment
    • 6.2.5. Analysis by Type of Software and Mode of Deployment
    • 6.2.6. Analysis by Scale of Operation
    • 6.2.7. Analysis by Type of Software and Scale of Operation
    • 6.2.8. Analysis by Regulatory Guidelines Followed
    • 6.2.9. Analysis by Type of End-User
    • 6.2.10. Analysis by Type of Software and End-User
  • 6.3. Cell and Gene Therapy Supply Chain Software: Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Year of Establishment and Company Size
    • 6.3.4. Analysis by Location of Headquarters
    • 6.3.5. Analysis by Number of Software Solutions Offered
    • 6.3.6. Most Active Players: Analysis by Number of Software Solutions Offered

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Parameters
  • 7.3. Methodology
  • 7.4. Company Competitiveness Analysis: Cell and Gene Therapy Supply Chain Software Providers
    • 7.4.1 COP Developers
    • 7.4.2. EMS Developers
    • 7.4.3. IMS Developers
    • 7.4.4. LIMS Developers
    • 7.4.5. LMS Developers
    • 7.4.6. PMS Developers
    • 7.4.7. QMS Developers
    • 7.4.8. TTS Developers

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Leading Players in Cell and Gene Therapy Supply Chain Software Market
    • 8.2.1. Azenta Life Sciences
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Supply Chain Management Solutions Portfolio
      • 8.2.1.3. Financial Information
      • 8.2.1.4. Recent Developments and Future Outlook
    • 8.2.2. NMDP BioTherapies
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Supply Chain Management Solutions Portfolio
      • 8.2.2.3. Financial Information
      • 8.2.2.4. Recent Developments and Future Outlook
    • 8.2.3. Biocair
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Supply Chain Management Solutions Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
    • 8.2.4. BioLife Solutions
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Supply Chain Management Solutions Portfolio
      • 8.2.4.3. Financial Information
      • 8.2.4.4. Recent Developments and Future Outlook
    • 8.2.5. CareDx
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Supply Chain Management Solutions Portfolio
      • 8.2.5.3. Financial Information
      • 8.2.5.4. Recent Developments and Future Outlook
    • 8.2.6. Cryoport
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Supply Chain Management Solutions Portfolio
      • 8.2.6.3. Financial Information
      • 8.2.6.4. Recent Developments and Future Outlook
    • 8.2.7. Lonza
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Supply Chain Management Solutions Portfolio
      • 8.2.7.3. Financial Information
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. TraceLink
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Supply Chain Management Solutions Portfolio
      • 8.2.8.4. Recent Developments and Future Outlook
    • 8.2.9. TrakCel
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Supply Chain Management Solutions Portfolio
      • 8.2.9.3. Recent Developments and Future Outlook
    • 8.2.10. Veeva Systems
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Supply Chain Management Solutions Portfolio
      • 8.2.10.3. Financial Information
      • 8.2.10.4. Recent Developments and Future Outlook
  • 8.3. Other Leading Players in Cell and Gene Therapy Supply Chain Software Market
    • 8.3.1. Emerson
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Supply Chain Management Solutions Portfolio
    • 8.3.2. LabVantage Solutions
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Supply Chain Management Solutions Portfolio
    • 8.3.3. Marken
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Supply Chain Management Solutions Portfolio
    • 8.3.4. MasterControl
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Supply Chain Management Solutions Portfolio
    • 8.3.5. QuickSTAT
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Supply Chain Management Solutions Portfolio
    • 8.3.6. Siemens
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Supply Chain Management Solutions Portfolio
    • 8.3.7. Stafa Cellular Therapy
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Supply Chain Management Solutions Portfolio
    • 8.3.8. Steiner
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Supply Chain Management Solutions Portfolio
    • 8.3.9. STEMSOFT Software
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Supply Chain Management Solutions Portfolio
    • 8.3.10. TECHNIDATA
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Supply Chain Management Solutions Portfolio
    • 8.3.11. Thermo Fisher Scientific
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Supply Chain Management Solutions Portfolio

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Funding Models
  • 9.3. Cell and Gene Therapy Supply Chain Software: Funding and Investment Analysis
    • 9.3.1. Analysis by Year of Funding
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Type of Funding and Amount Invested
    • 9.3.5. Analysis of Amount Invested by Year and Type of Funding
    • 9.3.6. Analysis by Geography
    • 9.3.7. Most Active Players: Analysis by Number of Instances
    • 9.3.8. Most Active Players: Analysis by Amount Raised
    • 9.3.9. Key Investors: Analysis by Number of Funding Instances
    • 9.3.10. Analysis by Type of Investor
  • 9.5. Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Cell and Gene Therapy Supply Chain Software: Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Year and Type of Partnership
    • 10.3.4. Analysis by Type of Partnership and Company Size
    • 10.3.5. Analysis by Type of Partner
    • 10.3.6. Analysis by Type of Software Involved
    • 10.3.7. Most Active Players: Analysis by Number of Partnerships
    • 10.3.8. Analysis by Geography
      • 10.3.8.1. Local and International Agreements
      • 10.3.8.2. Intracontinental and Intercontinental Agreements

11. PLATFORM UTILIZATION AGREEMENTS IN SUPPLY CHAIN SOFTWARE SOLUTIONS MARKET

  • 11.1. Chapter Overview
  • 11.2. Platform Utilization Agreements in Supply Chain Software Solutions Market: List of Agreements
    • 11.2.1. Analysis by Year of Agreement
    • 11.2.2. Analysis by Type of Partner
    • 11.2.3. Analysis by Type of Software Involved
    • 11.2.4. Analysis by Type of Partner and Type of Software Involved
    • 11.2.5. Analysis of Partners by Geography
    • 11.2.5. Most Active Players: Analysis by Number of Platform Utilization Agreements

12. STAKEHOLDER NEEDS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Cell and Gene Therapy Supply Chain: Needs of Different Stakeholders
    • 12.2.1. Comparison of Stakeholder Needs
    • 12.2.2. Conclusion

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 13.1. Chapter Overview
  • 13.2. Market Drivers
  • 13.3. Market Restraints
  • 13.4. Market Opportunities
  • 13.5. Market Challenges
  • 13.6. Conclusion

14. GLOBAL CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET

  • 14.1. Chapter Overview
  • 14.2. Assumptions and Methodology
  • 14.3. Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 14.3.1. Scenario Analysis
      • 14.3.1.1. Conservative Scenario
      • 14.3.1.2. Optimistic Scenario
  • 14.4. Key Market Segmentations
  • 14.5. Dynamic Dashboard

15. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY PROCESS COMPONENT

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035
    • 15.3.1. Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
    • 15.3.2. Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 15.3.3. Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 15.3.4. Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 15.4. Data Triangulation and Validation

16. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF SOFTWARE

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035
    • 16.3.1. Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.2. Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.3. Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.4. Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.5. Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.6. Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 16.3.7. Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.4. Data Triangulation and Validation

17. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY MODE OF DEPLOYMENT

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035
    • 17.3.1. Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 17.3.2. Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 17.4. Data Triangulation and Validation

18. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY SCALE OF OPERATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035
    • 18.3.1. Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 18.3.2. Cell and Gene Therapy Supply Chain Software Market for Commercial Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 18.4. Data Triangulation and Validation

19. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF END-USER

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035
    • 19.3.1. Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 19.3.2. Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 19.3.3. Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 19.3.4. Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 19.4. Data Triangulation and Validation

20. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
    • 20.3.1. Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.1.1. Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.1.2. Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2. Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.2.1. Cell and Gene Therapy Supply Chain Software Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.2.2. Cell and Gene Therapy Supply Chain Software Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.2.3. Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.2.4. Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.2.5. Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.2.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3. Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.3.1. Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.3.2. Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.3.3. Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.3.4. Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.3.5. Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.3.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.4. Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.4.1. Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.4.2. Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.4.3. Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
      • 20.3.4.4. Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 20.4. Data Triangulation and Validation

21. CONCLUSION

22. EXECUTIVE INSIGHTS

  • 22.1. Chapter Overview
  • 22.2. TrakCel
    • 22.2.1. Company Snapshot
    • 22.2.2. Interview Transcript: Martin Lamb, (Former Chief Business Officer)
  • 22.3. Cell and Gene Therapy Catapult
    • 22.3.1. Company Snapshot
    • 22.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
  • 22.4. McKesson
    • 22.4.1. Company Snapshot
    • 22.4.2. Interview Transcript: Divya Iyer, Former Senior Director, Corporate Strategy and Business Development
  • 22.5. Inlog
    • 22.5.1. Company Snapshot
    • 22.5.2. Interview Transcript: David Delay, International Sales and Transfusion Manager
  • 22.6. Thermo Fisher Scientific
    • 22.6.1. Company Snapshot
    • 22.6.2. Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 5.1 Therapeutic Applications of Cell Therapies
  • Table 6.1 Cell and Gene Therapy Supply Chain Software: Information on Type of Software and Key Features Offered
  • Table 6.3 Cell and Gene Therapy Supply Chain Software: Information on Application Area
  • Table 6.4 Cell and Gene Therapy Supply Chain Software: Information on Mode of Deployment and Scale of Operation
  • Table 6.5 Cell and Gene Therapy Supply Chain Software: Information on Regulatory Guidelines Followed
  • Table 6.6 Cell and Gene Therapy Supply Chain Software: Information on Type of End-User
  • Table 6.7 List of Cell and Gene Therapy Supply Chain Software Developers
  • Table 8.1 Cell and Gene Therapy Supply Chain Software: List of Companies Profiled
  • Table 8.2 Cell and Gene Therapy Supply Chain Software: List of Other Leading Players
  • Table 8.3 Azenta Life Sciences: Company Overview
  • Table 8.4 Azenta Life Sciences: Supply Chain Management Solutions Portfolio
  • Table 8.5 Azenta Life Sciences: Recent Developments and Future Outlook
  • Table 8.6 NMDP BioTherapies: Company Overview
  • Table 8.7 NMDP BioTherapies: Supply Chain Management Solutions Portfolio
  • Table 8.8 NMDP BioTherapies: Recent Developments and Future Outlook
  • Table 8.9 Biocair: Company Overview
  • Table 8.10 Biocair: Supply Chain Management Solutions Portfolio
  • Table 8.11 Biocair: Recent Developments and Future Outlook
  • Table 8.12 BioLife Solutions: Company Overview
  • Table 8.13 BioLife Solutions: Supply Chain Management Solutions Portfolio
  • Table 8.14 BioLife Solutions: Recent Developments and Future Outlook
  • Table 8.15 CareDx: Company Overview
  • Table 8.16 CareDx: Supply Chain Management Solutions Portfolio
  • Table 8.17 CareDX: Recent Developments and Future Outlook
  • Table 8.18 Cryoport: Company Overview
  • Table 8.19 Cryoport: Supply Chain Management Solutions Portfolio
  • Table 8.20 Cryoport: Recent Developments and Future Outlook
  • Table 8.21 Lonza: Company Overview
  • Table 8.22 Lonza: Supply Chain Management Solutions Portfolio
  • Table 8.23 Lonza: Recent Developments and Future Outlook
  • Table 8.24 TraceLink: Company Overview
  • Table 8.25 TraceLink: Supply Chain Management Solutions Portfolio
  • Table 8.26 TraceLink: Recent Developments and Future Outlook
  • Table 8.27 TrakCel: Company Overview
  • Table 8.28 TrakCel: Supply Chain Management Solutions Portfolio
  • Table 8.29 TrakCel: Recent Developments and Future Outlook
  • Table 8.30 Veeva Systems: Company Overview
  • Table 8.31 Veeva Systems: Supply Chain Management Solutions Portfolio
  • Table 8.32 Veeva Systems: Recent Developments and Future Outlook
  • Table 8.33 Emerson: Company Overview
  • Table 8.34 Emerson: Supply Chain Management Solutions Portfolio
  • Table 8.35 LabVantage Solutions: Company Overview
  • Table 8.36 LabVantage Solutions: Supply Chain Management Solutions Portfolio
  • Table 8.37 Marken: Company Overview
  • Table 8.38 Marken: Supply Chain Management Solutions Portfolio
  • Table 8.39 MasterControl: Company Overview
  • Table 8.40 MasterControl: Supply Chain Management Solutions Portfolio
  • Table 8.41 QuickSTAT: Company Overview
  • Table 8.42 QuickSTAT: Supply Chain Management Solutions Portfolio
  • Table 8.43 Siemens: Company Overview
  • Table 8.44 Siemens: Supply Chain Management Solutions Portfolio
  • Table 8.45 Stafa Cellular Therapy: Company Overview
  • Table 8.46 Stafa Cellular Therapy: Supply Chain Management Solutions Portfolio
  • Table 8.47 Steiner: Company Overview
  • Table 8.48 Steiner: Supply Chain Management Solutions Portfolio
  • Table 8.49 STEMSOFT Software: Company Overview
  • Table 8.50 STEMSOFT Software: Supply Chain Management Solutions Portfolio
  • Table 8.51 TECHNIDATA: Company Overview
  • Table 8.52 TECHNIDATA: Supply Chain Management Solutions Portfolio
  • Table 8.53 Thermo Fisher Scientific: Company Overview
  • Table 8.54 Thermo Fisher Scientific: Supply Chain Management Solutions Portfolio
  • Table 9.1 Cell and Gene Therapy Supply Chain Software: List of Funding and Investments, 2014-2023
  • Table 10.1 Cell and Gene Therapy Supply Chain Software: List of Partnerships and Collaborations, 2019-2024
  • Table 11.1 Cell and Gene Therapy Supply Chain Software: List of Platform Utilization Agreements, 2019-2024
  • Table 22.1 TrakCel: Company Snapshot
  • Table 22.2 Cell and Gene Therapy Catapult: Company Snapshot
  • Table 22.3 McKesson: Company Snapshot
  • Table 22.4 Inlog: Company Snapshot
  • Table 22.5 Thermo Fisher Scientific: Company Snapshot
  • Table 23.1 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software
  • Table 23.2 Cell and Gene Therapy Supply Chain Software: Distribution by Key Features
  • Table 23.3 Cell and Gene Therapy Supply Chain Software: Distribution by Application Area
  • Table 23.4 Cell and Gene Therapy Supply Chain Software: Distribution by Mode of Deployment
  • Table 23.5 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Mode of Deployment
  • Table 23.6 Cell and Gene Therapy Supply Chain Software: Distribution by Scale of Operation
  • Table 23.7 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Scale of Operation
  • Table 23.8 Cell and Gene Therapy Supply Chain Software: Distribution by Regulatory Guidelines Followed
  • Table 23.9 Cell and Advanced Therapies Supply Chain Management Software: Distribution by Type of End-User
  • Table 23.10 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Type of End-User
  • Table 23.11 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment
  • Table 23.12 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Company Size
  • Table 23.13 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment and Company Size
  • Table 23.14 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Region)
  • Table 23.15 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Country)
  • Table 23.16 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Number of Software Solutions Offered
  • Table 23.17 Most Active Players: Distribution by Number of Software Solutions Offered
  • Table 23.18 Azenta Life Sciences: Annual Revenues, FY 2020-FY 2023 (USD Million)
  • Table 23.19 NMDP BioTherapies: Annual Revenues, FY 2019 - FY 2022 (USD Million)
  • Table 23.20 BioLife Solutions: Annual Revenues, FY 2020 - FY 2023 (USD Million)
  • Table 23.21 CareDx: Annual Revenues, FY 2018 - FY 2021 (USD Million)
  • Table 23.22 Cryoport: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
  • Table 23.23 Lonza: Annual Revenues, FY 2019 - FY 2023 (CHF Million)
  • Table 23.24 Veeva Systems: Annual Revenues, FY 2020 - FY 2023 (USD Million)
  • Table 23.25 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2023
  • Table 23.26 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2023 (USD Million)
  • Table 23.27 Funding and Investment Analysis: Distribution by Type of Funding, 2014-2023
  • Table 23.28 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
  • Table 23.29 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2014-2023
  • Table 23.30 Funding and Investment Analysis: Geographical Distribution of Funding Instances and Amount Invested
  • Table 23.31 Funding and Investment Analysis: Geographical Distribution of Funding Instances (Country)
  • Table 23.32 Most Active Players: Distribution by Number of Funding Instances
  • Table 23.33 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 23.34 Key Investors: Distribution by Number of Funding Instances
  • Table 23.35 Funding and Investment Analysis: Distribution by Type of Investor
  • Table 23.36 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2019-2024
  • Table 23.37 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 23.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 23.39 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
  • Table 23.40 Partnerships and Collaborations: Distribution by Type of Software Involved
  • Table 23.41 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 23.42 Most Active Players: Distribution by Number of Partnerships
  • Table 23.43 Partnerships and Collaborations: Local and International Agreements
  • Table 23.44 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Table 23.45 Platform Utilization Agreements: Cumulative Year-wise Trend of Agreements, 2019-2024
  • Table 23.46 Platform Utilization Agreements: Distribution by Type of Partner
  • Table 23.47 Platform Utilization Agreements: Distribution by Type of Software Involved
  • Table 23.48 Platform Utilization Agreements: Distribution by Type of Partner and Type of Software Involved
  • Table 23.49 Platform Utilization Agreements: Distribution of Partners by Geography
  • Table 23.50 Most active Players: Distribution by Number of Platform Utilization Agreements
  • Table 23.51 Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) (USD Million)
  • Table 23.52 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.53 Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035 (USD Million)
  • Table 23.54 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) (USD Million)
  • Table 23.55 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.56 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) (USD Million)
  • Table 23.57 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.58 Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) (USD Million)
  • Table 23.59 Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.60 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) (USD Million)
  • Table 23.61 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Forecasted Estimates (2024-2035), Conservative,Base and Optimistic Scenarios (USD Million)
  • Table 23.62 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035 (USD Million)
  • Table 23.63 Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) (USD Million)
  • Table 23.64 Cell and Gene Therapy Supply Chain Software Market for EMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.65 Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) (USD Million)
  • Table 23.66 Cell and Gene Therapy Supply Chain Software Market for LIMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.67 Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) (USD Million)
  • Table 23.68 Cell and Gene Therapy Supply Chain Software Market for IMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.69 Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) (USD Million)
  • Table 23.70 Cell and Gene Therapy Supply Chain Software Market for COP: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.71 Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) (USD Million)
  • Table 23.72 Cell and Gene Therapy Supply Chain Software Market for QMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.73 Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) (USD Million)
  • Table 23.74 Cell and Gene Therapy Supply Chain Software Market for LMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.75 Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) (USD Million)
  • Table 23.76 Cell and Gene Therapy Supply Chain Software Market for PMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.77 Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035 (USD Million)
  • Table 23.78 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) (USD Million)
  • Table 23.79 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USDMillion)
  • Table 23.80 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) (USD Million)
  • Table 23.81 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.82 Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Million)
  • Table 23.83 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) (USD Million)
  • Table 23.84 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.85 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale: Historical Trends (2018-2023) (USD Million)
  • Table 23.86 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.87 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035 (USD Million)
  • Table 23.88 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) (USD Million)
  • Table 23.89 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.90 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) (USD Million)
  • Table 23.91 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.92 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) (USD Million)
  • Table 23.93 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.94 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) (USD Million)
  • Table 23.95 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.96 Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Million)
  • Table 23.97 Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) (USD Million)
  • Table 23.98 Cell and Gene Therapy Supply Chain Software Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.99 Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) (USD Million)
  • Table 23.100 Cell and Gene Therapy Supply Chain Software Market in the US: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.101 Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) (USD Million)
  • Table 23.102 Cell and Gene Therapy Supply Chain Software Market in Canada: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.103 Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) (USD Million)
  • Table 23.104 Cell and Gene Therapy Supply Chain Software Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.105 Cell and Gene Therapy Supply Chain Management Software Market in the UK: Historical Trends (2018-2023) (USD Million)
  • Table 23.106 Cell and Gene Therapy Supply Chain Management Software Market in the UK: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.107 Cell and Gene Therapy Supply Chain Management Software Market in Germany: Historical Trends (2018-2023) (USD Million)
  • Table 23.108 Cell and Gene Therapy Supply Chain Management Software Market in Germany: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.109 Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) (USD Million)
  • Table 23.110 Cell and Gene Therapy Supply Chain Software Market in France: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.111 Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) (USD Million)
  • Table 23.112 Cell and Gene Therapy Supply Chain Software Market in Italy: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.113 Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) (USD Million)
  • Table 23.114 Cell and Gene Therapy Supply Chain Software Market in Switzerland: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.115 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) (USD Million)
  • Table 23.116 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.117 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) (USD Million)
  • Table 23.118 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.119 Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) (USD Million)
  • Table 23.120 Cell and Gene Therapy Supply Chain Software Market in Australia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.121 Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) (USD Million)
  • Table 23.122 Cell and Gene Therapy Supply Chain Software Market in China: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.123 Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) (USD Million)
  • Table 23.124 Cell and Gene Therapy Supply Chain Software Market in Japan: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.125 Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) (USD Million)
  • Table 23.126 Cell and Gene Therapy Supply Chain Software Market in India: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.127 Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) (USD Million)
  • Table 23.128 Cell and Gene Therapy Supply Chain Software Market in South Korea: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.129 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) (USD Million)
  • Table 23.130 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.131 Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) (USD Million)
  • Table 23.132 Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.133 Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) (USD Million)
  • Table 23.134 Cell and Gene Therapy Supply Chain Software Market in New Zealand: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.135 Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) (USD Million)
  • Table 23.136 Cell and Gene Therapy Supply Chain Software Market in Brazil: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.137 Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) (USD Million)
  • Table 23.138 Cell and Gene Therapy Supply Chain Software Market in Israel: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.139 Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) (USD Million)
  • Table 23.140 Cell and Gene Therapy Supply Chain Software Market in Other Countries: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentations
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Cell and Gene Therapy Supply Chain Software Market Landscape
  • Figure 4.2 Executive Summary: Funding and Investment Analysis
  • Figure 4.3 Executive Summary: Partnerships and Collaborations
  • Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Classification of Advanced Therapy Medicinal Products
  • Figure 5.2 Difference between Cell / Advanced Therapies and Other Biotechnology Products
  • Figure 5.3 Components in the Cell and Gene Therapy Supply Chain
  • Figure 5.4 Software Solutions for Cell and Gene Therapy Supply Chain Management
  • Figure 5.5 Key Challenges in Cell and Gene Therapy Supply Chain
  • Figure 6.1 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software
  • Figure 6.2 Cell and Gene Therapy Supply Chain Software: Distribution by Key Features
  • Figure 6.3 Cell and Gene Therapy Supply Chain Software: Distribution by Application Area
  • Figure 6.4 Cell and Gene Therapy Supply Chain Software: Distribution by Mode of Deployment
  • Figure 6.5 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Mode of Deployment
  • Figure 6.6 Cell and Gene Therapy Supply Chain Software: Distribution by Scale of Operation
  • Figure 6.7 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Scale of Operation
  • Figure 6.8 Cell and Gene Therapy Supply Chain Software: Distribution by Regulatory Guidelines Followed
  • Figure 6.9 Cell and Advanced Therapies Supply Chain Management Software: Distribution by Type of End-User
  • Figure 6.10 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Type of End-User
  • Figure 6.11 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment
  • Figure 6.12 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Company Size
  • Figure 6.13 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment and Company Size
  • Figure 6.14 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Region)
  • Figure 6.15 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Country)
  • Figure 6.16 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Number of Software Solutions Offered
  • Figure 6.17 Most Active Players: Distribution by Number of Software Solutions Offered
  • Figure 7.1 Company Competitiveness Analysis: COP Developers
  • Figure 7.2 Company Competitiveness Analysis: EMS Developers
  • Figure 7.3 Company Competitiveness Analysis: IMS Developers
  • Figure 7.4 Company Competitiveness Analysis: LIMS Developers
  • Figure 7.5 Company Competitiveness Analysis: LMS Developers
  • Figure 7.6 Company Competitiveness Analysis: PMS Developers
  • Figure 7.7 Company Competitiveness Analysis: QMS Developers
  • Figure 7.8 Company Competitiveness Analysis: TTS Developers
  • Figure 8.1 Azenta Life Sciences: Annual Revenues, FY 2020-FY 2023 (USD Million)
  • Figure 8.2 NMDP BioTherapies: Annual Revenues, FY 2019-FY 2022 (USD Million)
  • Figure 8.3 BioLife Solutions: Annual Revenues, FY 2020-FY 2023 (USD Million)
  • Figure 8.4 CareDx: Annual Revenues, FY 2018-FY 2021 (USD Million)
  • Figure 8.5 Cryoport: Annual Revenues, FY 2019-9M FY 2023 (USD Million)
  • Figure 8.6 Lonza: Annual Revenues, FY 2019-FY 2023 (CHF Million)
  • Figure 8.7 Veeva Systems: Annual Revenues, FY 2020 - FY 2023 (USD Million)
  • Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2023
  • Figure 9.2 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2023 (USD Million)
  • Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 9.4 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
  • Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2014-2023
  • Figure 9.6 Funding and Investment Analysis: Geographical Distribution of Funding Instances and Amount Invested
  • Figure 9.7 Funding and Investment Analysis: Geographical Distribution of Funding Instances (Country)
  • Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.9 Most Active Players: Distribution by Amount Raised (USD Million)
  • Figure 9.10 Key Investors: Distribution by Number of Funding Instances
  • Figure 9.11 Funding and Investment Analysis: Distribution by Type of Investor
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2019-2024
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
  • Figure 10.5 Partnerships and Collaborations: Distribution by Type of Software Involved
  • Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 10.8 Partnerships and Collaborations: Local and International Agreements
  • Figure 10.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 11.1 Platform Utilization Agreements: Cumulative Year-wise Trend of Agreements, 2019-2024
  • Figure 11.2 Platform Utilization Agreements: Distribution by Type of Partner
  • Figure 11.3 Platform Utilization Agreements: Distribution by Type of Software Involved
  • Figure 11.4 Platform Utilization Agreements: Distribution by Type of Partner and Type of Software Involved
  • Figure 11.5 Platform Utilization Agreements: Distribution of Partners by Geography
  • Figure 11.6 Most active Players: Distribution by Number of Platform Utilization Agreements
  • Figure 12.1 Cell and Gene Therapy Supply Chain: Stakeholder Needs
  • Figure 12.2 Relative Importance of Stakeholders Needs
  • Figure 13.1 Cell and Gene Therapy Supply Chain Software: Market Drivers
  • Figure 13.2 Cell and Gene Therapy Supply Chain Software: Market Restraints
  • Figure 13.3 Cell and Gene Therapy Supply Chain Software: Market Opportunities
  • Figure 13.4 Cell and Gene Therapy Supply Chain Software: Market Challenges
  • Figure 14.1 Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 14.2 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
  • Figure 14.3 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
  • Figure 15.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035 (USD Million)
  • Figure 15.2 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 15.3 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 15.4 Cell and Gene Therapy Supply Chain Software Market for Logistics Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 15.5 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software Solution, 2018, 2024 and 2035 (USD Million)
  • Figure 16.2 Cell and Gene Therapy Supply Chain Software Market for EMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.3 Cell and Gene Therapy Supply Chain Software Market for LIMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.4 Cell and Gene Therapy Supply Chain Software Market for IMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.5 Cell and Gene Therapy Supply Chain Software Market for COP, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.6 Cell and Gene Therapy Supply Chain Software Market for QMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.7 Cell and Gene Therapy Supply Chain Software Market for LMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 16.8 Cell and Gene Therapy Supply Chain Software Market for PMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 17.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035 (USD Million)
  • Figure 17.2 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 17.3 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 18.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Million)
  • Figure 18.2 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 18.3 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 19.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035 (USD Million)
  • Figure 19.2 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 19.3 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 19.4 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 19.5 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Million)
  • Figure 20.2 Cell and Gene Therapy Supply Chain Software Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.3 Cell and Gene Therapy Supply Chain Software Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.4 Cell and Gene Therapy Supply Chain Software Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.5 Cell and Gene Therapy Supply Chain Software Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.6 Cell and Gene Therapy Supply Chain Management Software Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.7 Cell and Gene Therapy Supply Chain Management Software Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.8 Cell and Gene Therapy Supply Chain Software Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.9 Cell and Gene Therapy Supply Chain Software Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.10 Cell and Gene Therapy Supply Chain Software Market in Switzerland, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.11 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.12 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.13 Cell and Gene Therapy Supply Chain Software Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.14 Cell and Gene Therapy Supply Chain Software Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.15 Cell and Gene Therapy Supply Chain Software Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.16 Cell and Gene Therapy Supply Chain Software Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.17 Cell and Gene Therapy Supply Chain Software Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.18 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.19 Cell and Gene Therapy Supply Chain Software Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.20 Cell and Gene Therapy Supply Chain Software Market in New Zealand, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.21 Cell and Gene Therapy Supply Chain Software Market in Brazil, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.22 Cell and Gene Therapy Supply Chain Software Market in Israel, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 20.23 Cell and Gene Therapy Supply Chain Software Market in Other Countries, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
  • Figure 21.1 Conclusion: Cell and Gene Therapy Supply Chain Software Market Landscape
  • Figure 21.2 Conclusion: Funding and Investment Analysis
  • Figure 21.3 Conclusion: Partnerships and Collaborations
  • Figure 21.4 Conclusion: Market Forecast and Opportunity Analysis